Introduction

Invasive ductal carcinoma (IDC) constitutes approximately 80% of breast cancer cases in the United States. After treatment, there is a 3-15% chance that IDC will recur.

Forecasting the recurrence of a patient's IDC as early as possible is critical for long term survival [2].

Previously, histopathological analyses were used to diagnose cancers and assess prognosis. These methods are often unable to integrate multiple data types or handle large amounts of genomic data.

Engineering Goal and Objective


We hypothesized that mRNA expression data could be used to predict IDC recurrence at least one decade in advance.

Our engineering goal was to build and train machine learning models on mRNA expression data to predict IDC recurrence with high accuracy, precision, and recall.

Dataset

Patient genomic and clinical samples collected in TCGA's Breast Invasive Carcinoma study were downloaded from cBioPortal [3].

The dataset contained 1084 patient samples, of which 856 samples were non-recurrent, 84 were recurrent, and 144 were not categorized. Genomic data was profiled about 11 years, on average, before IDC recurred.



Predictive Modeling for Invasive Ductal Carcinoma Recurrence


Rohan Kaushikan, Sindhu Ghanta

International Electronic Conference on Cancer 2024

Methodology


XGBoost and Random forest, both tree based models, are efficient on datasets with a small number of features such as the one used in this study. Additionally, both models have a Feature Importance Analysis tool that offers interpretability of the model's prediction process.

Differential mRNA expression analysis: T-tests used to calculate t-values for each gene's mRNA expression between cohorts. The 10 with lowest p-values (all < 0.05) were selected as features. Rows with null values were removed. An XGBoost and Random Forest model were trained and used for prediction.



While they are both based on an ensemble of decision trees, XGBoost learns sequentially while Random Forest trains decision trees independently.

<u>Results</u>




allowed better performance of the XGBoost model.

Random Forest model's performance on validation set for threshold values between 0 and 1 through ROC curves.

The XGBoost model with hyper parameters n_estimators = 400 and max_depth = 3 had the best performance on the testing dataset, with accuracy 0.84, recall 0.29, and precision 0.89. This indicates that a higher number of simpler decision trees allows for best model performance on our dataset. Our results are promising in that they indicate that by reducing skew in the dataset or by including more samples, model performance can be improved. While we were able to predict IDC recurrence using machine learning with high precision, the recall was much lower than desirable, especially for a medical setting. However, identifying ~29% of patient cancers as recurrent using data collected 11 years prior to recurrence while maintaining high precision speaks to the potential of our model.

Ultimately, we aim to develop a model that can consistently and accurately predict IDC recurrence early, leading to improved outcomes for IDC patients.



Sample disease free (left) and cancer recurrent (right) patient tissue slide images from TCGA's BRCA study

Our future work includes the incorporation of tissue slide images for IDC recurrence prediction. This would result in a multimodal approach integrating multiple data types.


After inclusion of more genes as features, we also aim to use XGBoost's and Random Forest's Feature Importance Analysis to identify genes that are closely associated with IDC recurrence.

1.	Halima
	Outco
	https:/
2.	Visser,
	Systen
	public
	Societ
3.	CBioPa
	<u>id=brc</u>
4.	Ratan,
	progn
	neuro

Max Depth

Discussion and Conclusion

Prediction using our current dataset will likely yield similar results, but we believe that incorporation of clinical and imaging data will drastically improve model performance [4], eventually resulting in a desirably low false negative rate.



Future Research

Selected References

na, A., et al. Intraoperative Radiation Therapy for Early-Stage Breast Cancer: Updated omes from a Single-Institution Experience. Annals of surgical oncology, 31(2), 931–935. //doi.org/10.1245/s1043<u>4-023-14448-6</u>

, L. L., et al. (2019). Predictors of an Invasive Breast Cancer Recurrence after DCIS: A matic Review and Meta-analyses. Cancer epidemiology, biomarkers & prevention : a cation of the American Association for Cancer Research, cosponsored by the American ty of Preventive Oncology, 28(5), 835–845. <u>https://doi.org/10.1158/1055-9965.EPI-18-0976</u> Portal for Cancer Genomics. (n.d.-b). <u>https://www.cbioportal.org/study/summary?</u> ca tcga pan can atlas 2018

R., et al. (2023). Factors determining the requirement of surgical intervention and nosis in cases of traumatic bifrontal contusions: A prospective observational study. *Surgical* logy international, 14, 438. <u>https://doi.org/10.25259/SNI_754_2023</u>